Shots:
The BLA submission was based on the results from the P-I/II trial (n=171) & & P-II/III (QUILT 3032) study (n=84) evaluating N-803 + BCG in patients with bladder cancer
The results from the QUILT 3032 study demonstrated that the combination therapy allows a greater chance of avoiding bladder removal in patients. Additionally, N-803 is also being evaluated under the QUILT 2005 study for the treatment of BCG-naïve NMIBC
ImmunityBio’s N-803 + BCG has previously received BTD & FTD for the treatment of BCG-unresponsive NMIBC CIS
Ref: Businesswire | Image: ImmunityBio
